Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725361 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).
A NA study of Scleroderma, Systemic and n Ulcer, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00725361 is a NA study of Scleroderma, Systemic and n Ulcer that has completed, run by Stanford University. The registered enrollment target is 20 participants, below the 81-participant average among 6 other Scleroderma, Systemic trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00725361, a NA study of Scleroderma, Systemic and n Ulcer, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.
Conditions Studied
Interventions
- DRUG Ambrisentan
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725361
The ClinicalTrials.gov registry entry for NCT00725361 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 81-participant average among 6 other Scleroderma, Systemic trials with a reported enrollment target (75% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Scleroderma, Systemic appearing as the primary indexed condition, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00725361 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00725361 about?
NCT00725361 is a clinical study titled "A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).". This is a research study of an investigational drug called ambrisentan (Letairis) in the treatment and prevention of digital ulcers in patients with systemic sclerosis.
What is the current status of trial NCT00725361?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2008-06. Estimated completion is 2010-12.
What conditions does trial NCT00725361 study?
This clinical trial studies the following conditions: Scleroderma, Systemic, n Ulcer.
What interventions are being tested in trial NCT00725361?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00725361?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00725361 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
ACTIVE NOT RECRUITING · NA
-
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RECRUITING · Phase 2
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
-
Imatinib in Systemic Sclerosis
COMPLETED · Phase 1
-
Study of Silicone-Associated Connective Tissue Diseases
COMPLETED
-
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.